Stock Analysis

NanoEntek, Inc.'s (KOSDAQ:039860) 29% Share Price Surge Not Quite Adding Up

NanoEntek, Inc. (KOSDAQ:039860) shareholders would be excited to see that the share price has had a great month, posting a 29% gain and recovering from prior weakness. Looking back a bit further, it's encouraging to see the stock is up 27% in the last year.

Following the firm bounce in price, NanoEntek may be sending very bearish signals at the moment with a price-to-earnings (or "P/E") ratio of 56.8x, since almost half of all companies in Korea have P/E ratios under 13x and even P/E's lower than 7x are not unusual. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the highly elevated P/E.

With earnings growth that's exceedingly strong of late, NanoEntek has been doing very well. It seems that many are expecting the strong earnings performance to beat most other companies over the coming period, which has increased investors’ willingness to pay up for the stock. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.

See our latest analysis for NanoEntek

pe-multiple-vs-industry
KOSDAQ:A039860 Price to Earnings Ratio vs Industry December 9th 2025
We don't have analyst forecasts, but you can see how recent trends are setting up the company for the future by checking out our free report on NanoEntek's earnings, revenue and cash flow.
Advertisement

How Is NanoEntek's Growth Trending?

In order to justify its P/E ratio, NanoEntek would need to produce outstanding growth well in excess of the market.

Taking a look back first, we see that the company grew earnings per share by an impressive 271% last year. Still, incredibly EPS has fallen 75% in total from three years ago, which is quite disappointing. Accordingly, shareholders would have felt downbeat about the medium-term rates of earnings growth.

Weighing that medium-term earnings trajectory against the broader market's one-year forecast for expansion of 38% shows it's an unpleasant look.

In light of this, it's alarming that NanoEntek's P/E sits above the majority of other companies. It seems most investors are ignoring the recent poor growth rate and are hoping for a turnaround in the company's business prospects. There's a very good chance existing shareholders are setting themselves up for future disappointment if the P/E falls to levels more in line with the recent negative growth rates.

The Final Word

NanoEntek's P/E is flying high just like its stock has during the last month. Typically, we'd caution against reading too much into price-to-earnings ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.

Our examination of NanoEntek revealed its shrinking earnings over the medium-term aren't impacting its high P/E anywhere near as much as we would have predicted, given the market is set to grow. When we see earnings heading backwards and underperforming the market forecasts, we suspect the share price is at risk of declining, sending the high P/E lower. If recent medium-term earnings trends continue, it will place shareholders' investments at significant risk and potential investors in danger of paying an excessive premium.

Before you take the next step, you should know about the 2 warning signs for NanoEntek that we have uncovered.

If P/E ratios interest you, you may wish to see this free collection of other companies with strong earnings growth and low P/E ratios.

Valuation is complex, but we're here to simplify it.

Discover if NanoEntek might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About KOSDAQ:A039860

NanoEntek

Engages in the research and development, production, and sale of life-science lab equipment, in vitro diagnostic medical devices, point of care diagnostic devices, and related consumables and solutions in Korea and internationally.

Flawless balance sheet with solid track record.

Advertisement

Weekly Picks

RO
RockeTeller
SCZ logo
RockeTeller on Santacruz Silver Mining ·

Crazy Undervalued 42 Baggers Silver Play (Active & Running Mine)

Fair Value:CA$8696.7% undervalued
75 users have followed this narrative
7 users have commented on this narrative
21 users have liked this narrative
RO
Robbo
FID logo
Robbo on Fiducian Group ·

Fiducian: Compliance Clouds or Value Opportunity?

Fair Value:AU$121.2% undervalued
13 users have followed this narrative
0 users have commented on this narrative
1 users have liked this narrative
WO
WVVI logo
woodworthfund on Willamette Valley Vineyards ·

Willamette Valley Vineyards (WVVI): Not-So-Great Value

Fair Value:US$245.0% overvalued
11 users have followed this narrative
0 users have commented on this narrative
1 users have liked this narrative

Updated Narratives

NO
S5L logo
Norms70 on Standard Lithium ·

SLI is share to watch next 5 years

Fair Value:€4.57.6% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
davidlsander
BEAM logo
davidlsander on Beam Therapeutics ·

The "Molecular Pencil": Why Beam's Technology is Built to Win

Fair Value:US$15081.9% undervalued
61 users have followed this narrative
3 users have commented on this narrative
0 users have liked this narrative
RE
PRME logo
RedhawkCC on Prime Medicine ·

PRME remains a long shot but publication in the New England Journal of Medicine helps.

Fair Value:US$0.0469.1k% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

TH
TheWallstreetKing
MVIS logo
TheWallstreetKing on MicroVision ·

MicroVision will explode future revenue by 380.37% with a vision towards success

Fair Value:US$6098.5% undervalued
118 users have followed this narrative
11 users have commented on this narrative
22 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$250.3925.9% undervalued
962 users have followed this narrative
6 users have commented on this narrative
25 users have liked this narrative
RO
RockeTeller
SCZ logo
RockeTeller on Santacruz Silver Mining ·

Crazy Undervalued 42 Baggers Silver Play (Active & Running Mine)

Fair Value:CA$8696.7% undervalued
75 users have followed this narrative
7 users have commented on this narrative
21 users have liked this narrative